SCHEMBL22652926

SCHEMBL22652926

CNc1ncc2cc(-c3cc(NC(=O)C(=O)OCc4ccccc4)cnc3C)cnc2n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.42
▸ KDR P35968 3/20 0.41
▸ KRAS P01116 2/20 0.41
▸ RAF1 P04049 2/20 0.41
▸ BRAF P15056 2/20 0.41
▸ TSHR P16473 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ BTK Q06187 9/20 0.37
▸ EGFR P00533 2/20 0.36
▸ BLK P51451 1/20 0.36
▸ JAK3 P52333 2/20 0.35
▸ LCK P06239 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ JAK2 O60674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22652928 0.90 KDR (0.44) ALDH1A1KDRKRASRAF1BRAF
SCHEMBL22625559 0.89 RAF1 (0.43) ALDH1A1KDRKRASRAF1BRAF
SCHEMBL22625561 0.84 KDR (0.59) ALDH1A1KDRKRASRAF1BRAF
SCHEMBL22625605 0.82 RAF1 (0.49) ALDH1A1KDRKRASRAF1BRAF
SCHEMBL22625543 0.75 BRAF (0.60) ALDH1A1KDRKRASRAF1BRAF
SCHEMBL24367126 0.74 ALDH1A1 (0.55) ALDH1A1TSHRRAB9ASMN1; SMN2BTK
SCHEMBL22612837 0.72 LCK (0.65) KDRRAF1BRAFJAK3LCK
SCHEMBL22625600 0.72 ALDH1A1 (0.37) ALDH1A1TSHRRAB9ASMN1; SMN2BTK
SCHEMBL22625601 0.71 KDR (0.42) KDRKRASRAF1BRAFJAK3
SCHEMBL22612778 0.71 LCK (0.47) KDRKRASRAF1BRAFJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 — — US disclosed
WO-2020227020-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2020-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667634-B2 Inhibitors of RAF kinases BRAF, RAF1, NRAS ALDH1A1 3044/4885KDR 113/4885KRAS 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback